3 completed, 1 terminated. 4 Phase 2.
By phase and status
Follow selgantolimod: new trials by email Literature Review of selgantolimod trials Research Report on selgantolimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV Selgantolimod, Placebo - Hepatitis B, HIV Infections Phase 2 Terminated 29 2023-05-01 2026-11-17
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) Tenofovir Alafenamide, VIR-2218, Nivolumab - Chronic Hepatitis B Phase 2 Completed 103 2021-08-14 2025-07-24
Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment Placebo, Selgantolimod, TAF - Chronic Hepatitis B Phase 2 Completed 67 2018-08-28 2022-05-10
Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy - Chronic Hepatitis B Phase 2 Completed 48 2018-04-06 2021-08-19
Conditions studied Hepatitis B, Chronic (3) · HIV Infections (1) · Hepatitis B (1)
Sponsors Gilead Sciences (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Countries New Zealand (2) · South Korea (2) · Thailand (2) · United States (2) · Australia (1) · Brazil (1) · Canada (1) · Denmark (1) · Hong Kong (1) · Peru (1) · Singapore (1) · Taiwan (1) · United Kingdom (1)
Results publications PMID 38133554